Cytalux
Phase 3Small molecule
Cytalux is one of 32 small molecule programs targeting Intraoperative. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Intraoperative
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
IC-Green
PProvepharm SAS
Approved
Ketalar
AAultman Health Foundation
Approved
Anerem
AAcacia Pharma Ltd
Approved
Reglan
IIstituto Clinico Humanitas
Approved
Ciprofol
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Marcaine
IInnocoll
Phase 2
MS Contin
HHikma Pharmaceuticals LLC
Phase 2
Vancocin
HHikma Pharmaceuticals LLC
Phase 2
Cytalux
OOn Target Laboratories, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intraoperative1 trial
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Recruiting·—·Phase 1·NCT06235125·10 enrolled
Gastrointestinal1 trial
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Recruiting·—·Phase 4·NCT07124351·15 enrolled
Endometrial Cancer1 trial
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Recruiting·—·Phase 1·NCT07278986·10 enrolled
Lung1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cytalux. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOn Target Laboratories, LLC